

1 **Determination of vancomycin pharmacokinetic/pharmacodynamic target and**
2 **individualized dosing regimen recommendation in ICU neonates**

3

4 Zhe Tang,^a Wei-wei Shuai,^a Jing-jing Li,^c Yan-xia Yu,^c Miao Qian,^b Xin Tong,^a Jing Cao,^{a#}
5 Zheng Jiao^{d#}

6 ^aDepartment of Pharmacy, Women's Hospital of Nanjing Medical University, Nanjing
7 Maternity and Child Health Care Hospital, Nanjing, China

8 ^bDepartment of Neonatology, Women's Hospital of Nanjing Medical University, Nanjing
9 Maternity and Child Health Care Hospital, Nanjing, China

10 ^cDepartment of Pharmacy, Suzhou Municipal Hospital, Suzhou, China

11 ^dDepartment of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University,
12 Shanghai, China

13

14 Running Head: PK/PD target of vancomycin in ICU neonates

15

16 #Correspondence

17 Zheng Jiao, jiaozhen@online.sh.cn

18 Jing Cao, njfyj@163.com.

19

20 **ABSTRACT**

21 A Bayesian-derived area-under-the-curve from 0 to 24 h to minimum inhibitory
22 concentration (AUC_{24}/MIC) of 400 to 600 has been recommended as the
23 pharmacokinetic/pharmacodynamic (PK/PD) target of vancomycin (VAN) treatment in
24 adults. However, limited data exists in neonates to support this target. Therefore, this study
25 aimed: (i) to develop a population PK model to characterize significant covariates and to
26 estimate AUC; (ii) to determine the neonatal PK/PD target of VAN and potential influence
27 factors on this target; (iii) to design neonatal VAN recommendation based on the evaluated
28 target. A single center retrospective observational cohort study was conducted. A
29 population PK model was established by using Monolix 2019R2. Acute kidney injury (AKI)
30 for all 182 patients were screened to determine the upper limit of VAN exposure. Clinical
31 efficacy of 42 patients with blood culture proved staphylococcal sepsis was analyzed, and
32 the threshold in predicting efficacy was developed as the lower limit of exposure. AUC_{24}
33 ≥ 623 (mg·h)/liter and concomitant use of VAS were independent risks for AKI. When
34 adjusted by current body weight (cWT) < 1.3 kg, $AUC_{24}/MIC < 242$ was highly
35 correlated with treatment failure. AUC_{24}/MIC of 250 to 600 with MIC assumed to 1
36 mg/liter was set as the optimal PK/PD target in neonates then dosing recommendation was
37 designed. In conclusion, AUC_{24}/MIC is a good predictor for VAN toxicity and efficacy in
38 neonates. The designed regimens are valuable for neonatal individualized dosing in ICU
39 setting. (This study has been registered at chictr.org.cn under identifier
40 ChiCTR1900027919.)

41 **Key words:** vancomycin, neonate, PK/PD, population PK modeling, AKI, efficacy

42 INTRODUCTION

43 Neonates are predisposed to late-onset neonatal sepsis (LOS) owing to their compromised
44 immune function and medical interventions. *Staphylococcus aureus* and other
45 *Staphylococcus spp.* are predominant pathogens leading to LOS. VAN, a glycopeptide
46 antibiotic developed many years ago, remains the agent of choice against staphylococcal
47 sepsis for patients in neonatal intensive care units (NICU) (1).

48 AUC_{24}/MIC has been identified as the most predictive PK/PD index of VAN treatment (2).
49 Trough-based target is no longer recommended due to studies of efficacy and
50 nephrotoxicity (3). Moreover, this target is regarded unreliable because of its interval-
51 dependent nature (4, 5). American Society of Health-System Pharmacists (ASHP) has
52 advocated a Bayesian-derived AUC/MIC ratio of 400 to 600 (assuming MIC of 1 mg/liter)
53 as the target for adults infected by methicillin-resistant *S. aureus* (MRSA) (3). However,
54 there is paucity of evidence in literature to guide the optimal exposure target in neonates.

55 VAN is a well-known potential renal toxic agent, while the breakpoint of its exposure in
56 predicting AKI, to our knowledge, has not been reported in neonates. $AUC > 800$
57 (mg·h)/liter was considered associated with the increased risk of nephrotoxicity in children
58 (6). This target was often used as the upper limit of VAN exposure to design dosing
59 regimen in neonates without solid validation in clinical studies (7). Additional risk of
60 unnecessary overexposure may arise in this condition.

61 Controversies remain in VAN exposure required for clinical efficacy. $AUC/MIC > 400$
62 was reported not related to improved outcomes and a relationship between AUC/MIC and

63 treatment failure failed to be established in pediatrics as well (8). Whether $AUC/MIC >$
64 400 is a necessary exposure for neonates is urgent to be verified.

65 Therefore, this study aimed: (i) to develop a population PK model to characterize
66 significant covariates and to estimate AUC; (ii) to determine the neonatal PK/PD target of
67 VAN and potential influence factors on this target; (iii) to design neonatal VAN
68 recommendation based on the evaluated target to facilitate individualized dosing in regular
69 NICU practice.

70

71 **RESULTS**

72 **Study population**

73 There were 185 neonates administered by intermittent intravenous infusion of VAN under
74 therapeutic drug monitoring (TDM) in NICU of Nanjing Maternity and Child Health Care
75 Hospital from 1st January 2016 to 31st December 2019. One hundred and eighty-two
76 patients were eligible for this study with 286 trough and 125 peak concentrations monitored
77 within the calibration range of analytical instrument. Two patients with incomplete clinical
78 data and the sole patient suffered from hematological malignancy were excluded. The study
79 flow was presented in Fig. 1.

80 All of patients were diagnosed as neonatal sepsis by clinical physicians with empirical
81 VAN application. About half of patients were co-medicated meropenem (MEM) and 36
82 individuals were received vasoactive drugs (VAS). The major comorbidities comprised
83 patent ductus arteriosus (PDA), pneumonia, bronchopulmonary dysplasia (BDP),

84 meningitis, neonatal necrotic enterocolitis (NEC) and persistent pulmonary hypertension
85 of newborn (PPHN). The mortality of the whole population was 15 (8.24%).

86 **Population PK modeling**

87 A population PK model was developed to estimate PK parameters of patients. One
88 compartment model with first-order elimination was enough to fit the data set. A
89 proportional model was chosen as the residual model. Various models, including base
90 model (Model I), simple exponent model (Model II), sigmoid function model (Model III),
91 age-dependent exponent (ADE) model (Model IV) and body weight-dependent exponent
92 (BDE) model (Model V), were investigated to screen the covariates of body size (9). The
93 detailed process was summarized in Table S1.

94 Postmenstrual age (PMA) appeared to reflect VAN clearance (CL) variability better than
95 gestational age (GA) or postnatal age (PNA) alone. The performance of sigmoid function
96 (Model III) was not superior to the simple exponent function (Model II) with time-varying
97 cWT and PMA, and ADE and BDE models (Model IV and V) seemed ill-conditioning and
98 overparameterized. Therefore, Model II was selected for further analysis due to the lower
99 Akaike information criteria (AIC) and Bayesian information criteria (BIC) compared to
100 other ones.

101 Serum creatinine (SCR), creatinine clearance (CLCR), and co-administration of VAS were
102 recognized as significant covariates on CL. Since SCR and CLCR were apparently
103 correlated with each other and were almost equally-performed, SCR was retained on
104 account of better accessibility in clinic. CL showed a 14% decrease with co-medicating

105 VAS. Moreover, cWT was added to volume of distribution (V) for physiologic plausibility
106 (equation 1), and CL was illustrated in equation 2.

107
$$V = V_{pop} \times \left(\frac{cWT}{1.5}\right) \quad (1)$$

108
$$CL = CL_{pop} \times \left(\frac{cWT}{1.5}\right)^{0.75} \times \left(\frac{PMA}{32}\right)^{beta1} \times \left(\frac{30}{SCR}\right)^{beta2} \times F_{VAS} \quad (2)$$

109 Where V is volume of distribution of VAN, V_{pop} is the population estimate of V, cWT is
110 the current body weight, CL is clearance, CL_{pop} is population estimate of CL, PMA is
111 postmenstrual age, SCR is serum creatinine, and F_{VAS} is the scaling factor for co-
112 medication of VAS.

113 Goodness-of-fit plots for the base model and final model were illustrated in Fig. 2. In
114 contrast to the base model, plot of the final model showed no obvious bias or trend and
115 much improved. The plots of normalized prediction distribution error (NPDE) were
116 presented in Fig. S1. The histogram and probability density plot met the normality well,
117 indicating a good fit of the model to individual data (Fig. S1). In the bootstrap process of
118 2000 time runs, the median parameter estimates were close to the final model (Table S2).
119 99% runs were successful, and bias in fixed effects were less than 5%, indicating that the
120 final model was stable and able to redetermine the estimates of population PK parameters.

121 Twenty-eight patients from Li's study were included for external evaluation of the
122 established model (10). In this data set, all the observations collected were troughs. The
123 medians of cWT, PMA, and SCR were 1.66 kg (range, 0.80 to 2.52 kg), 33.22 weeks (range,
124 28.28 to 36.71 wk), and 35.42 $\mu\text{mol/liter}$ (range, 14.17 to 51.71 $\mu\text{mol/liter}$) respectively.
125 No patient was co-administered VAS. Mean prediction error (MPE) and mean absolute

126 prediction error (MAPE) of the final model was 3.97% (SD, 19.88%) and 13.01% (SD,
127 15.36%) respectively.

128 Since the external showed no obvious bias of the established model, we combined all the
129 data and re-estimate the PK parameters. The estimates of the PK parameters did not show
130 an apparent difference (Table 1).

131 **Determination of the PK/PD target**

132 **(i) AKI analysis.** AKI occurrence was screened for all the patients (Fig. 1). Generally,
133 most of patients were not prescribed renal toxic agents besides VAN. VAS was the major
134 nephrotoxin with the prescription for 36 individuals. Other typical renal toxic agents, like
135 furosemide and ibuprofen, were applied for 30 and 8 patients respectively.

136 Seven patients were observed AKI during VAN treatment. Once AKI discovered, VAN
137 dosage adjustments were executed by physicians immediately. Except 2 deaths, renal
138 function of 5 survivals with initial impairment recovered as a lag decrease of SCR within
139 5 days of therapy.

140 Not unexpectedly, AKI patients had suppressed renal function with abnormally higher SCR,
141 lower CLCR and VAN CL. AUC_{24} of them were dramatically elevated though there was
142 no statistical difference in daily dose between AKI and non-AKI individuals (Table 2, Fig.
143 3). Most other characteristics were generally similar. In contrast to non-AKI patients, AKI
144 patients were more likely to be prescribed by MEM, VAS, and furosemide. AKI patients
145 also had a smaller PNA and a higher morbidity of PDA (Table 2).

146 AUC₂₄ was confirmed strongly correlated with AKI in univariate logistic regression (ULR)
147 (P<0.01) (Table 3). AUC₂₄ of 623 (mg·h)/liter was detected as the threshold for AKI of by
148 ROC analysis (Table 3, Fig. 4). This indicated AUC₂₄ was a good predictor for AKI
149 occurrence. PNA, PPHN, and concomitant use of VAS or furosemide were found as
150 potential influence factors of AKI besides AUC₂₄ (Table S3). Significant correlation
151 between AUC₂₄ and C_{min} (trough concentration) was identified (Spearman coefficient =
152 0.88, P < 0.01). Therefore, C_{min} was not included for further analysis. SCR and CLCR were
153 also excluded because they were diagnostic criteria of AKI. In multivariate logistic
154 regression (MLR), independent predictors of AKI included AUC₂₄ ≥ 623 (mg·h)/liter and
155 concomitant use of VAS (Table 4).

156 **(ii) Efficacy analysis.** Seventy-nine patients had positive blood culture results among the
157 whole population. Thirty-one patients with blood culture proved non-staphylococcal sepsis,
158 4 patients with polymicrobial infections, and 2 patients co-administered anti-infective
159 sensitive to the identified staphylococcus were excluded. Finally, 42 individuals with blood
160 culture proved staphylococcal sepsis were eligible for efficacy analysis (Fig. 1). Sixteen
161 individuals of them infected by *S. aureus*, and others by *other Staphylococcus spp.*

162 Seven patients experienced treatment failure. Three were dead during VAN therapy and 4
163 were observed with positive blood culture at ≥ 5 days after VAN started. Linezolid (LZD)
164 therapies were then applied as an alternative for them with satisfied clinical outcomes.
165 None with recurrence of bacteremia was observed during their hospital stay.

166 Most patients with ineffective treatment were very-low-birth-weight (VLBW) ones
167 compared to effective patients including both low-birth-weight (LBW) and normal-birth-

168 weight (NBW) individuals. Mortality of ineffective individuals was also higher, while all
169 effective members were survived. Despite insignificant difference in daily dosage and
170 MICs, AUC_{24}/MIC were much lower among ineffective ones. (Table 2, Fig. 3).

171 AUC_{24}/MIC was found marginally significantly correlated with clinical efficacy ($P < 0.1$)
172 (Table 3). The threshold for efficacy identified by ROC curve was AUC_{24}/MIC of 242
173 (Table 3, Fig. 4). In ULR, bWT (birth weight) and cWT, two variables highly correlated,
174 seemed strongly associated with efficacy ($P < 0.05$) (Table S3). cWT was included in
175 MLR since it better reflected the actual physiological status when VAM was applied.
176 Results of MLR revealed that $cWT < 1.3$ kg and $AUC_{24}/MIC < 242$ were significant risk
177 factors of treatment failure.

178 **Dosing regimen design**

179 On the basis of statistical analysis above, VAN PK/PD target in neonates was set as
180 AUC_{24}/MIC of 250 to 600 with MIC assumed to 1 mg/liter. The dosage regimens
181 recommended by current references and this study were displayed in Table 5 and Table 6
182 respectively (11, 12).

183 According to results in Table 6, patients with concomitant use of VAS were required a
184 reduced daily dose. In general, dosing interval of 18 to 24 h was suitable for extremely
185 preterm patients ($PMA < 28$ wk) with single dosage of 10 to 20 mg/kg. For preterm ones
186 with PMA of 28 to 36 wk, proper dosing intervals varied from 12 to 18 h. It was enough
187 for term neonates with interval of 8 to 12 h. Interval shorter than 8 h seemed unnecessary.

188 Our results suggested daily dose of extremely-low-birth-weight (ELBW) neonates with
189 birth weight < 1 kg was 12.5 to 23 mg/kg. However, Neonatal Formulary recommended
190 a daily dose of 20 mg/kg for all ELBW neonates and the maximum daily dose of Red Book
191 for these patients was 30 mg/kg. Quite a number of ELBW neonates were obviously
192 overdosed in these references (Table 5). Table 6 also showed a daily dose of 20 to 52.5
193 mg/kg was required for NBW neonates with birth weight > 2.7 kg and SCR ≤ 60 μ
194 mol/liter. While Red Book claimed a daily dose of 30 mg/kg for patients (GA > 28 wk)
195 with normal renal function (SCR < 61.7 μ mol/liter) (Table 5). It was apparent that this
196 regimen was unable to satisfy the treatment need of large proportional NBW neonates.

197

198 **DISCUSSION**

199 AUC₂₄/MIC of 400 to 600 has been identified as the recommended PK/PD target in adults
200 while few studies incorporating population PK modeling were conducted to determine or
201 verify PK/PD target for VAN treatment in neonates (2, 3). In our study, a Bayesian-derived
202 target of AUC₂₄/MIC 250 to 600 has been established in neonatal population for the first
203 time and applied to design individualized dosing regimen.

204 In order to ensure the accuracy of PK parameter estimation, a population PK model has
205 been developed and evaluated. The clearance of a typical patient with cWT of 1.5 kg, PMA
206 of 32 weeks, SCR of 30 μ mol/liter, and without VAS co-medication is estimated to 0.06
207 liter/(h·kg). This value is consistent with the range of 0.04 to 0.10 liter/(h·kg) from previous
208 VAN population PK reports in neonates, and no obvious ethnic difference is observed (10,

209 13-20). The results of external evaluation also confirm that the predictive ability is
210 satisfying.

211 The recommended PK/PD target in adults is determined by AUC_{24} estimated using
212 validated Bayesian method and MICs obtained by broth microdilution method (BMD)
213 approach (3). Achievement of our target complies with exactly the same method. This
214 allows us to compare these two targets obtained from different populations directly. It is
215 noticed that the lower limit of target for neonates is relatively lower (AUC/MIC of 250 vs.
216 400) and two target ranges are overlapped in some extent. The threshold in predicting VAN
217 efficacy is obtained on the basis of staphylococcal sepsis in this study, while VAN
218 treatment in neonates with staphylococcal infections is rarely reported to fail (3). It is
219 reasonable that a lower AUC_{24}/MIC ratio target is also possible to be effective for neonates
220 with staphylococcal LOS.

221 Our population PK model has identified VAS as an indicator of decreased VAN CL. The
222 application of VAS for ICU neonates has also been reported as an independent risk factor
223 for development of AKI (21). In our study, 85.7% (6/7) patients with AKI were co-
224 mediated with VAS. Zhao's study regards VAS as an indirect surrogate for the severity of
225 illness on account of its application often accompanied by decreased blood pressure and
226 hypoperfusion (22). AKI may be induced in such a pathophysiological condition.

227 Whether VAN has a direct renal toxic effect or whether high exposure is a consequence of
228 renal impairment is still under debate (23). Previous report illustrates that VAN-induced
229 nephrotoxicity does not exist alone but occurs when other nephrotoxins are co-
230 administered (6, 23), and the major nephrotoxin in our institution is VAS. Results of MLR

231 shows high VAN exposure of $AUC_{24} \geq 623$ (mg·h)/liter remains an independent predictor
232 of AKI after adjustment of concomitant use of VAS. Although our study cannot explain
233 whether the threshold for AKI will be varied by concomitant use of VAS, there is a reason
234 to believe both high VAN exposure and VAS application probably co-contribute the
235 development of AKI.

236 Seven (4%) cases of VAN-induced AKI were observed in this study within the range of 1
237 to 9% as former report (24). Except 2 deaths, renal functions of survivals were recovered
238 to normal level with the progress of treatment although VAN exposures were abnormally
239 high in a short period. The VAN dosage of them was kept monitoring and adjusted based
240 on TDM results. All survivals were recovered without other obvious ADRs during their
241 hospital stay. This finding agrees with the previous report in children (25). It indicates that
242 neonates may be relatively tolerant to high VAN exposure and renal impairments for them
243 are reversible. The ongoing monitoring of both VAN concentrations and SCR needs to be
244 emphasized during the treatment to ensure the discovery of AKI without delay and avoid
245 possible serious ADRs.

246 In the efficacy analysis, when adjusted by $cWT < 1.3$ kg, a clear association between
247 $AUC_{24}/MIC < 242$ and VAN treatment failure has been verified. Low-weight neonates,
248 especially individual weighted less than 1.5 kg, often means growth defects, higher
249 mortality and more morbidities (26). It is reasonable that low-weight neonates are more
250 likely to experience treatment failures.

251 The relationship between VAN exposure and clinical efficacy failed to establish in past
252 pediatric and neonatal studies (8, 27). The possible reasons for this disparity may be caused

253 by following points. Primarily, previous studies contain patients with various infection
254 sites while all patients in our study have bloodstream infection (8, 27). Considering several
255 breakpoints reported by studies on different infectious diseases in adults, the threshold of
256 AUC/MIC may be varied by different infection sites (28-30). Secondly, the whole
257 population in previous studies are under a relatively low VAN exposure (8, 27). The
258 correlation between efficacy and AUC₂₄/MIC ratio may not possible to be established due
259 to AUC₂₄/MIC ratios concentrated within a narrow range. The comparison of
260 characteristics of effective and ineffective patients reflects that main reason for treatment
261 failure is still inadequate VAN exposure (AUC₂₄).

262 In contrast to our study, regimens in current references seems over-simplified. The scheme
263 in Neonatal Formulary is merely PMA-based while regimen in Red Book is designed on
264 the basis of GA and SCR (11, 12). According to our population PK model, renal function
265 and concomitant use of VAS are significant covariates on VAN CL and unable to be out
266 of consideration in regimen design. GA alone is not enough to describe the maturation of
267 neonates and PMA is a better predictor for CL apparently. Overall, the current
268 recommended regimens from Neonatal Formulary and Red Book are inappropriate and
269 regimen designed in this study seemed more sophisticated and suitable for clinical practice.

270 There are several limitations in our study. First, PK/PD target found in this study gives no
271 consideration of bacterial resistance which needs the support of further microbiological
272 researches. Second, the sample size for the study is small especially for patients with AKI
273 or ineffective treatment. Although this did not affect our ability to find statistical
274 breakpoints in predicting AKI or VAN treatment failure, it is not a sufficiently robust

275 sample to support the established PK/PD target. Last but not the least, the retrospective
276 nature of this study may lead to confounding and bias that may well be avoided with
277 prospective study methods. Our findings need to be validated further in large multi-
278 centered prospective studies.

279

280 **CONCLUSION**

281 In conclusion, AUC_{24}/MIC is a good predictor for VAN toxicity and efficacy in neonates.
282 A Bayesian-derived AUC_{24}/MIC ratio of 250 to 600 is regarded as an appropriate PK/PD
283 target of VAN treatment assumed MIC to 1 in ICU neonates balancing treatment
284 achievement and AKI risks. AKI is more likely to occur when VAN is applied with
285 concomitant use of VAS. Underdose of VAN and low-weight of neonates co-contribute to
286 possible treatment failure. Individualized dosing regimens on the basis of the developed
287 target are valuable for clinical practice.

288

289 **METHODS**

290 **Study design**

291 A single center retrospective observational cohort study was conducted at Nanjing
292 Maternity and Child Health Care Hospital (Nanjing, China). The electronic medical records
293 of all patients who accepted VAN therapy in NICU from 1st January 2016 to 31st December
294 2019 were reviewed to determine eligibility.

295 This study was executed in accordance with the recommendations of the Declaration of
296 Helsinki (2000). The protocol was approved by the Ethics Committee of Nanjing Maternity
297 and Child Health Care Hospital. Identities of patients were hidden during the study.
298 Informed consent was approved unnecessary due to retrospective nature of the study. This
299 study was registered at chictr.org.cn under identifier ChiCTR1900027919.

300 **Study population**

301 Patients with postmenstrual age (PMA) \leq 48 weeks when VAN began were included. All
302 individuals were treated with VAN for at least three days and at least one serum
303 concentration was monitored. The exclusion criteria were as follows: Complete data were
304 unavailable; VAN serum concentrations were out of the calibration range of analytical
305 devices.

306 Information of interest included: GA, PNA, PMA, bWT, cWT, dosing history, VAN serum
307 concentration, SCR, CLCR calculated by Schwartz equation (31), co-medications
308 (especially concomitant use of nephrotoxins like VAS, non-steroidal anti-inflammatory
309 drugs, or loop diuretics), clinical diagnosis, radiographic examinations, laboratory tests and
310 microbiology culture.

311 According to the local protocol, neonates with suspected or confirmed sepsis received
312 empirical therapy with VAN in combination with MEM based on presumptive diagnosis.
313 Once a diagnosis was established, anti-infectives were rationalized to cover the causative
314 pathogen. Target trough levels of VAN according to local guidelines were 10 to 20 mg/liter
315 (32). As this was an observational and respective study, dosage adjustment based on TDM
316 results were determined at the discretion of treating physicians.

317 VAN (Vancocin, Lilly, S.A, Suzhou, China) was administered 10~15 mg/kg per time from
318 every 8 to 18 h with intermittent infusion lasting 60 min. Blood samples were monitored
319 half an hour before the start of vancomycin (trough concentration) or half an hour after the
320 completion of infusion (peak concentration). All the samples were collected prior to the
321 fourth or fifth dose (steady state). If the dosage was changed, it recommended TDM until
322 steady state was reached.

323 **Analytical method**

324 VAN concentrations were analyzed by fluorescence polarization immunoassay with an
325 ARCHITECT i2000SR (Abbott Laboratories, Chicago, IL, USA) within 24 h after samples
326 obtained. The limit of detection was 1 mg/liter, and the calibration range of this assay was
327 3 to 100 mg/liter. The intra-day and inter-day coefficients of variation (CV) were less than
328 20%. Any concentration out of calibration range were excluded from the study.

329 SCR samples were analyzed with enzymatic method by using Beckman Coulter AU5800
330 (Beckman Coulter Inc., Brea CA, USA). The calibration range was from 3 to 100 mg/liter.
331 The intra-day and inter-day CVs were less than 3.75%.

332 Etiological examinations were provided by clinical laboratory of our hospital by using
333 VITEK 2 microbial identification system (bioMérieux, Lyon, France). BMD method was
334 used to determine MICs. The interpretative reports were issued by the laboratory
335 technicians according to the criteria recommended by the Clinical Laboratory Standards
336 Institute (CLSI).

337 **Population PK modeling**

338 A population PK model was conducted among all individuals in this study to calculate PK
339 parameters precisely by using Monolix (version 2019R2, Lixoft, France). Stochastic
340 Approximation Expectation Maximization (SAEM) algorithm was used to estimate PK
341 parameters and their variability.

342 One or two compartment model with first-order elimination was tried to fit the dataset.
343 The interindividual variability of the pharmacokinetic parameters was estimated by using
344 an exponential model and was expressed as equation 3:

$$345 \quad P_i = P_{pop} \times e^{\eta_i} \quad (3)$$

346 where P_{pop} is the population typical value of parameter, and P_i refers to parameter value of
347 the i^{th} subject with random variable η_i , which is assumed normally distributed with a mean
348 of zero and variance of ω^2 .

349 Residual unexplained variability was tested by an additive model, exponential model, or a
350 combined additive and exponential model.

351 The potential covariates were investigated for their influence on PK parameters.
352 Considering the rapid changing pathophysiological status of neonates, all the covariates
353 were defined as time-varying ones (regressor in Monolix). Any categorical variable present
354 in less than 20% of the population was not going to be tested.

355 Five models were employed to describe the impacts of size (weight) and maturation (age)
356 on VAN CL (33). The performance of model fitting was investigated in further analysis.
357 Model I ~ III based on weight scaling of CL were tested using equation 4.

$$358 \quad CL_i = CL_{pop} \times \left(\frac{WT}{WT_{median}} \right)^{k_1} \times MF \quad (4)$$

359 where CL_i is the typical clearance of i^{th} individual, and CL_{pop} is population typical value of
360 VAN clearance. WT is the weight of i^{th} individual and WT_{median} is median weight of the
361 population. k_1 is the exponent. MF represents the maturation factor (MF) which defines the
362 maturing process. It is set to 1 for all the models except Model III.

363 *Model I:* in the base model, the exponent k_1 is fixed to 0.75 (34).

364 *Model II:* in the simple exponent model, the exponent k_1 is fixed to 0.75. Age (GA , PNA ,
365 and PMA) with exponential function is tested to explore the effect on VAN CL .

366 *Model III:* in the sigmoid maturation model, the exponent k_1 is fixed to 0.75 and MF is
367 calculated according to equation 5 (34).

368
$$MF = \frac{1}{1 + \left(\frac{Age}{MT_{50}}\right)^{\gamma}} \quad (5)$$

369 where MT_{50} is the value of age when maturation reaches 50 % of the adult clearance, and
370 γ is the Hill coefficient which controls the slope of sigmoid function.

371 *Model IV:* the ADE model (equation 6) (9).

372
$$k_1 = k_0 - \frac{k_{\text{max}} \times Age^{\gamma}}{k_{50}^{\gamma} + Age^{\gamma}} \quad (6)$$

373 *Model V:* the BDE model (equation 7) (35).

374
$$k_1 = k_0 - \frac{k_{\text{max}} \times WT^{\gamma}}{k_{50}^{\gamma} + WT^{\gamma}} \quad (7)$$

375 where k_0 is the value of the exponent at birth (0 years) (Model IV) or at a theoretical weight
376 of zero (Model V), k_{max} is the maximum decrease of the exponent, k_{50} is the age (Model

377 IV) or weight (Model V) at which a 50 % decrease in the maximum decrease is attained,
378 and γ is the Hill coefficient used to determine the steepness of the sigmoid decline.

379 Structural models were regarded preferential due to lower AIC and BIC (36). The selection
380 of covariates was determined using a forward selection process and a backward elimination
381 process. Nested covariate models were statistically compared using a likelihood ratio test
382 on the differences in the objective function value (OFV). A reduction in OFV of 3.84 ($p <$
383 0.05) for forward inclusion and an increase in OFV of 6.63 ($p < 0.01$) for backward
384 elimination were the criteria for retaining a covariate in the model.

385 Both internal validation and external validation were performed to verify the predictive
386 performance of the model. The final model was internally assessed by visual inspection of
387 goodness-of-fit plots, normalized prediction distribution error (NPDE) and bootstrap (36-
388 38). The NPDE distribution was expected to follow a normal distribution with a mean of 0
389 and a variance of 1. The bootstrap procedure was replicated 2000 runs with the R package
390 Rsmix (version 2.0.2, <https://cran.r-project.org/web/packages/Rsmix/index.html>). The
391 median values and 95% confidence intervals of PK parameters were compared with
392 estimates from the final model. Bias in fixed effects less than 5% was thought acceptable.
393 Bias (%) was calculated by equation 8:

394
$$Bias (\%) = \frac{Bootstrap\ median - final\ model\ estimate}{final\ model\ estimate} \times 100\% \quad (8)$$

395 The external data set of neonates from Li's research was used to validate the final model
396 (10). MAPE and MPE were applied to calculate bias and imprecision of predictive
397 performance (equation 9 and 10) (39). MAPE and MPE values within the range of 30%
398 and 20% respectively were considered acceptable for the final model.

399
$$MAPE(\%) = \frac{1}{N} \sum \left| \frac{IPRED_i - OBS_i}{OBS_i} \right| \quad (9)$$

400
$$MPE(\%) = \frac{1}{N} \sum \frac{IPRED_i - OBS_i}{OBS_i} \quad (10)$$

401 where $IPRED_i$ and OBS_i is individual prediction and the observation of the i^{th} subject, and
402 N is the number of subjects in the data set for external evaluation.

403 **Determination of the PK/PD target**

404 (i) **AKI analysis.** AKI occurrence of all the patients were screened. The association
405 between VAN exposure and AKI occurrence was investigated and the breakpoint in
406 predicting AKI was tried to discover as the upper limit of VAN exposure. AKI definition
407 for neonates were: an increase of SCR by 26.5 $\mu\text{mol/liter}$ within 48 h, or a SCR rise to \geq
408 1.5 times from the baseline within 7 days, or a urine volume $<0.5 \text{ ml}/(\text{kg}\cdot\text{h})$ for 6 hours
409 (40). AUC_{24} was calculated by equation 11.

410
$$AUC_{24} = \frac{\text{Daily dose}}{CL} \quad (11)$$

411 Where AUC_{24} is the Bayesian-derived area-under-the-curve from 0 to 24 h, and CL is VAN
412 clearance.

413 (ii) **Efficacy analysis.** Patients with blood culture proved staphylococcal sepsis were
414 assessed the qualification of efficacy analysis. Patients with the following characteristics
415 were excluded: length of VAN treatment less than 5 days, polymicrobial infection or
416 concomitant antimicrobial agent sensitive to the identified staphylococcus.

417 The clinical efficacy of eligible patients was analyzed. The correlation between VAN
418 steady exposure after dose adjustment and clinical efficacy was explored as well. The

419 breakpoint that provided the greatest difference in treatment failure was regarded as the
420 lower limit of VAN exposure. VAN treatment failure was defined as positive blood culture
421 at ≥ 5 days after initiation of vancomycin treatment, recurrence of bacteremia within 30
422 days, or 30-day mortality (29, 30, 41).

423 **Dosing regimen design**

424 The PK model-based dosing recommendations were designed by using the optimal
425 exposure target and were compared with current regimens in Neonatal Formulary and Red
426 Book (11, 12).

427 Virtual patients with different physiological characteristics (i.e, different levels of ages,
428 weights, or renal functions) were set for simulations. The PMA range of virtual patients
429 was designated from 25 to 46 weeks. Their corresponding weights were medians obtained
430 from the Fenton growth chart for neonates (42). 1000 replicates of each scenario were
431 simulated by MC method to detect the most proper dosing scheme (43). R package mlxR
432 (version 4.1.0, <https://cran.r-project.org/web/packages/mlxR/index.html>) was used to
433 complete this procedure.

434 **Statistical analysis**

435 Baseline characteristics and PK/PD parameters of patients were summarized. Continuous
436 variables were compared in Wilcoxon tests, and dichotomous variables in Fisher exact tests.
437 Threshold values of VAN exposure in predicting AKI or efficacy were identified from
438 Youden index (J) based on the receiver operating characteristic (ROC) analysis. J =
439 maximum (sensitivity + specificity - 1) (44).

440 ULR analyses were performed to test the correlation between variables and AKI
441 occurrence or treatment failure. Potentially significant variables identified by ULR ($P <$
442 0.2) were included into MLR to identify predictors for AKI or efficacy (45). If variables
443 were correlated, only one was included into the analysis. For variables exerting significant
444 effects on AKI or efficacy, ROC analysis was employed to find cut-off values to create
445 dichotomous variables for better professional explanation (46).

446 All statistical analyses were executed by R. $P < 0.05$ was considered as statistically
447 significant. pROC package was used for ROC analysis (version 1.15.3, [https://cran.r-](https://cran.r-project.org/web/packages/pROC/index.html)
448 [project.org/web/packages/pROC/index.html](https://cran.r-project.org/web/packages/pROC/index.html)).

449

450 **DATA AVAILABILITY**

451 The data of this study will be open to public through public access of ResMan
452 (<http://www.medresman.org.cn/pub/cn/proj/projectshshow.aspx?proj=1448>) within 6
453 months after publication.

454

455 **ACKNOWLEDGEMENTS**

456 The authors would like to thank Dr Xiao-jun Ji (Nanjing Chia Tai Tianqing Pharmaceutical
457 Co., Ltd., Nanjing, China) for his assistance with figure plotting.

458

459 **FUNDING**

460 This project was partly supported by the National Science Foundation for Young Scientists
461 of China (No.) and Hospital Pharmacy Foundation of Nanjing Pharmaceutical Association
462 (No. 2019YX004).

463

464 **CONFLICTS OF INTEREST**

465 All authors declare no conflicts of interest.

466

467

468

469

470

471

472

473

474

475

476

477

478

479 **REFERENCES**

- 480 1. Jacqz-Aigrain E, Zhao W, Sharland M, van den Anker JN. 2013. Use of
481 antibacterial agents in the neonate: 50 years of experience with vancomycin
482 administration. *Semin Fetal Neonatal Med* 18:28-34.
- 483 2. Rybak M, Lomaestro B, Rotschafer JC, Moellering R, Jr., Craig W, Billeter M,
484 Dalovisio JR, Levine DP. 2009. Therapeutic monitoring of vancomycin in adult
485 patients: a consensus review of the American Society of Health-System
486 Pharmacists, the Infectious Diseases Society of America, and the Society of
487 Infectious Diseases Pharmacists. *Am J Health Syst Pharm* 66:82-98.
- 488 3. Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, Mueller BA, Pai MP,
489 Wong-Beringer A, Rotschafer JC, Rodvold KA, Maples HD, Lomaestro BM. 2020.
490 Therapeutic monitoring of vancomycin for serious methicillin-resistant
491 *Staphylococcus aureus* infections: A revised consensus guideline and review by the
492 American Society of Health-System Pharmacists, the Infectious Diseases Society
493 of America, the Pediatric Infectious Diseases Society, and the Society of Infectious
494 Diseases Pharmacists. *Am J Health Syst Pharm* doi:10.1093/ajhp/zxaa036.
- 495 4. Patel N, Pai MP, Rodvold KA, Lomaestro B, Drusano GL, Lodise TP. 2011.
496 Vancomycin: we can't get there from here. *Clin Infect Dis* 52:969-974.
- 497 5. Matsumoto K, Takesue Y, Ohmagari N, Mochizuki T, Mikamo H, Seki M,
498 Takakura S, Tokimatsu I, Takahashi Y, Kasahara K, Okada K, Igarashi M,
499 Kobayashi M, Hamada Y, Kimura M, Nishi Y, Tanigawara Y, Kimura T. 2013.
500 Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus

- 501 review of the Japanese Society of Chemotherapy and the Japanese Society of
502 Therapeutic Drug Monitoring. *Journal of Infection and Chemotherapy* 19:365-380.
- 503 6. Le J, Ny P, Capparelli E, Lane J, Ngu B, Muus R, Romanowski G, Vo T, Bradley
504 J. 2015. Pharmacodynamic Characteristics of Nephrotoxicity Associated With
505 Vancomycin Use in Children. *J Pediatric Infect Dis Soc* 4:e109-e116.
- 506 7. Dao K, Guidi M, Andre P, Giannoni E, Basterrechea S, Zhao W, Fuchs A, Pfister
507 M, Buclin T, Csajka C. 2019. Optimisation of vancomycin exposure in neonates
508 based on the best level of evidence. *Pharmacol Res*
509 doi:10.1016/j.phrs.2019.104278:104278.
- 510 8. Hahn A, Frenck RW, Allen-Staat M, Zou Y, Vinks AA. 2015. Evaluation of Target
511 Attainment of Vancomycin Area Under the Curve in Children With Methicillin-
512 Resistant *Staphylococcus Aureus* Bacteremia. *Ther Drug Monit* 37:619-625.
- 513 9. Ding J, Wang Y, Lin W, Wang C, Zhao L, Li X, Zhao Z, Miao L, Jiao Z. 2014. A
514 Population Pharmacokinetic Model of Valproic Acid in Pediatric Patients with
515 Epilepsy: A Non-Linear Pharmacokinetic Model Based on Protein-Binding
516 Saturation. *Clin Pharmacokinet* 54:305-317.
- 517 10. Li JJ, Liu YX, Tang L, Weng XH, Wang SN, Jiao Z, Shang EN. 2017. Population
518 Pharmacokinetics of Vancomycin in Chinese Neonates. *Chin Pharm J* 52:1434-
519 1441.
- 520 11. Mills Q. 2014. *Neonatal Formulary 7: Drug Use in Pregnancy and the First Year of*
521 *Life*, 7 ed. Wiley Blackwell. BMJ., UK.

- 522 12. Pediatrics AAO, in Kimberlin DW, Brady MT, Jackson MA, (ed) LS. 2018. Red
523 Book: Report of the Committee on Infectious Diseases, 31 ed. Itasca, IL: American
524 Academy of Pediatrics, USA.
- 525 13. Seay RE, Brundage RC, Jensen PD, Schilling CG, Edgren BE. 1994. Population
526 pharmacokinetics of vancomycin in neonates. Clin Pharmacol Ther 56:169-175.
- 527 14. Kimura T, Sunakawa K, Matsuura N, Kubo H, Shimada S, Yago K. 2004.
528 Population pharmacokinetics of arbekacin, vancomycin, and panipenem in
529 neonates. Antimicrob Agents Chemother 48:1159-1167.
- 530 15. Anderson BJ, Allegaert K, Van den Anker JN, Cossey V, Holford NHG. 2007.
531 Vancomycin pharmacokinetics in preterm neonates and the prediction of adult
532 clearance. Br J Clin Pharmacol 63:75-84.
- 533 16. Lo YL, van Hasselt JG, Heng SC, Lim CT, Lee TC, Charles BG. 2010. Population
534 pharmacokinetics of vancomycin in premature Malaysian neonates: identification
535 of predictors for dosing determination. Antimicrob Agents Chemother 54:2626-
536 2632.
- 537 17. Marques-Minana MR, Saadeddin A, Peris JE. 2010. Population pharmacokinetic
538 analysis of vancomycin in neonates. A new proposal of initial dosage guideline. Br
539 J Clin Pharmacol 70:713-720.
- 540 18. Oudin C, Vialet R, Boulamery A, Martin C, Simon N. 2011. Vancomycin
541 prescription in neonates and young infants: toward a simplified dosage. Arch Dis
542 Child Fetal Neonatal Ed 96:F365-370.

- 543 19. Zhao W, Lopez E, Biran V, Durrmeyer X, Fakhoury M, Jacqz-Aigrain E. 2012.
544 Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic
545 drug monitoring. *Arch Dis Child* 98:449-453.
- 546 20. Li ZL, Liu YX, Jiao Z, Qiu G, Huang JQ, Xiao YB, Wu SJ, Wang CY, Hu WJ, Sun
547 HJ. 2018. Population Pharmacokinetics of Vancomycin in Chinese ICU Neonates:
548 Initial Dosage Recommendations. *Front Pharmacol* 9:603.
- 549 21. Stojanovic V, Barisic N, Milanovic B, Doronjski A. 2014. Acute kidney injury in
550 preterm infants admitted to a neonatal intensive care unit. *Pediatr Nephrol* 29:2213-
551 20.
- 552 22. Zhao W, Hill H, Le Guellec C, Neal T, Mahoney S, Paulus S, Castellan C, Kassai
553 B, van den Anker JN, Kearns GL, Turner MA, Jacqz-Aigrain E, Consortium T.
554 2014. Population pharmacokinetics of ciprofloxacin in neonates and young infants
555 less than three months of age. *Antimicrob Agents Chemother* 58:6572-6580.
- 556 23. Chavada R, Ghosh N, Sandaradura I, Maley M, Van Hal SJ. 2017. Establishment
557 of an AUC 0–24 Threshold for Nephrotoxicity Is a Step towards Individualized
558 Vancomycin Dosing for Methicillin-Resistant *Staphylococcus aureus* Bacteremia.
559 *Antimicrob Agents Chemother* 61.
- 560 24. Lestner JM, Hill LF, Heath PT, Sharland M. 2016. Vancomycin toxicity in neonates:
561 a review of the evidence. *Curr Opin Infect Dis* 29:237-247.
- 562 25. Le J, Vaida F, Nguyen E, Adler-Shohet FC, Romanowski G, Kim J, Vo T,
563 Capparelli EV. 2014. Population-Based Pharmacokinetic Modeling of Vancomycin
564 in Children with Renal Insufficiency. *J Pharmacol Clin Toxicol* 2:1017-1026.

- 565 26. A. GC, E. JS. 2018. Avery's Diseases of the Newborn, 10 ed. Elsevier Inc,
566 Philadelphia, PA.
- 567 27. Padari H, Oselin K, Tasa T, Metsvaht T, Loivukene K, Lutsar I. 2016. Coagulase
568 negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose
569 or target? BMC Pediatr 16:206.
- 570 28. Gawronski KM, Goff DA, Jack B, Khadem TM, Bauer KA. 2013. A Stewardship
571 Program's Retrospective Evaluation of Vancomycin AUC₂₄/MIC and Time to
572 Microbiological Clearance in Patients with Methicillin-Resistant Staphylococcus
573 aureus Bacteremia and Osteomyelitis. Clinical Therapeutics 35:772-779.
- 574 29. Jung Y, Song KH, Cho J, Kim HS, Kim NH, Kim TS, Choe PG, Chung JY, Park
575 WB, Bang JH, Kim ES, Park KU, Park SW, Kim HB, Kim NJ, Oh MD. 2014. Area
576 under the concentration-time curve to minimum inhibitory concentration ratio as a
577 predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus
578 aureus bacteraemia. Int J Antimicrob Agents 43:179-183.
- 579 30. Casapao AM, Lodise TP, Davis SL, Claeys KC, Kullar R, Levine DP, Rybak MJ.
580 2015. Association between vancomycin day 1 exposure profile and outcomes
581 among patients with methicillin-resistant Staphylococcus aureus infective
582 endocarditis. Antimicrob Agents Chemother 59:2978-2985.
- 583 31. Schwartz GJ, Brion LP, Spitzer A. 1987. The Use of Plasma Creatinine
584 Concentration for Estimating Glomerular Filtration Rate in Infants, Children, and
585 Adolescents. Pediatric Clinics of North America 34:571-590.
- 586 32. Ye Z-K, Chen Y-L, Chen K, Zhang X-L, Du G-H, He B, Li D-K, Liu Y-N, Yang
587 K-H, Zhang Y-Y, Zhai S-D. 2016. Therapeutic drug monitoring of vancomycin: a


- 588 guideline of the Division of Therapeutic Drug Monitoring, Chinese
589 Pharmacological Society. *Journal of Antimicrobial Chemotherapy* 71:3020-3025.
- 590 33. Jacqz-Aigrain E, Leroux S, Zhao W, van den Anker JN, Sharland M. 2015. How to
591 use vancomycin optimally in neonates: remaining questions. *Expert Rev Clin*
592 *Pharmacol* 8:635-648.
- 593 34. Holford N, Heo YA, Anderson B. 2013. A pharmacokinetic standard for babies and
594 adults. *J Pharm Sci* 102:2941-2952.
- 595 35. Wang C, Peeters MY, Allegaert K, Blusse van Oud-Alblas HJ, Krekels EH, Tibboel
596 D, Danhof M, Knibbe CA. 2012. A bodyweight-dependent allometric exponent for
597 scaling clearance across the human life-span. *Pharm Res* 29:1570-1581.
- 598 36. Byon W, Smith MK, Chan P, Tortorici MA, Riley S, Dai H, Dong J, Ruiz-Garcia
599 A, Sweeney K, Cronenberger C. 2013. Establishing Best Practices and Guidance in
600 Population Modeling: An Experience With an Internal Population Pharmacokinetic
601 Analysis Guidance. *CPT Pharmacometrics Syst Pharmacol* 2:e51.
- 602 37. Ette EI. 1997. Stability and performance of a population pharmacokinetic model. *J*
603 *Clin Pharmacol* 37:486-495.
- 604 38. Comets E, Brendel K, Mentré F. 2008. Computing normalised prediction
605 distribution errors to evaluate nonlinear mixed-effect models: The npde add-on
606 package for R. *Comput Methods Programs Biomed* 90:154-166.
- 607 39. van der Meer AF MM, Touw DJ, Proost JH, Neef C. 2011. Optimal Sampling
608 Strategy Development Methodology Using Maximum A Posteriori Bayesian
609 Estimation. *Ther Drug Monit* 33:133-146.

- 610 40. Khwaja A. 2012. KDIGO clinical practice guidelines for acute kidney injury.
611 Nephron Clin Pract 120:c179-184.
- 612 41. Al-Sulaiti FK, Nader AM, Saad MO, Shaukat A, Parakadavathu R, Elzubair A, Al-
613 Badriyeh D, Elewa H, Awaisu A. 2019. Clinical and Pharmacokinetic Outcomes of
614 Peak-Trough-Based Versus Trough-Based Vancomycin Therapeutic Drug
615 Monitoring Approaches: A Pragmatic Randomized Controlled Trial. Eur J Drug
616 Metab Pharmacokinet 44:639-652.
- 617 42. Fenton TR, Sauve RS. 2007. Using the LMS method to calculate z-scores for the
618 Fenton preterm infant growth chart. Eur J Clin Nutr 61:1380-5.
- 619 43. Trang M, Dudley MN, Bhavnani SM. 2017. Use of Monte Carlo simulation and
620 considerations for PK-PD targets to support antibacterial dose selection. Curr Opin
621 Pharmacol 36:107-113.
- 622 44. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, Muller M. 2011.
623 pROC: an open-source package for R and S+ to analyze and compare ROC curves.
624 BMC Bioinformatics 12:77.
- 625 45. Zhang Z. 2016. Model building strategy for logistic regression: purposeful selection.
626 Ann Transl Med 4:111.
- 627 46. Zhou ZR, Wang WW, Li Y, Jin KR, Wang XY, Wang ZW, Chen YS, Wang SJ,
628 Hu J, Zhang HN, Huang P, Zhao GZ, Chen XX, Li B, Zhang TS. 2019. In-depth
629 mining of clinical data: the construction of clinical prediction model with R. Ann
630 Transl Med 7:796.

631


632

633 **FIGURES**



634

635 **FIG 1** Study flow



636

637

638 **FIG 2** Goodness-of-fit plot.

639 (A) Population predictions vs. observations. (B) Individual predictions (IPRED) vs.

640 observations. (C) The time vs. the individual weighted residual errors (IWRES). (D) Serum

641 concentrations (Cc) vs. IWRES. The black solid lines are the reference lines, and yellow

642 solid lines are the loess smooth lines.


643

644

645

646


647



648

649 **FIG 3** Boxplots of VAN exposure parameters.

650 (A) Boxplot of AUC_{24} and occurrence of AKI. (B) Boxplot of AUC_{24}/MIC and VAN
651 efficacy. Bold lines mean medians and fine lines shows lower and upper quartiles. Black
652 color stands for AKI patients and red color for non-AKI ones. Orange color represents
653 effective individuals and blue color represents ineffective ones.



654

655 **FIG 4** ROC analysis.

656 (A) ROC curve in AKI analysis (B) ROC curve in efficacy analysis. AUC is area under the
657 curve.

658

659

660

661

662

663

664

665

666 **TABLES**

667 **TABLE 1** Results of population PK modeling

Parameter ^a	Original data set		New data set ^c	
	Value	RSE (%) ^b	Value	RSE (%)
Fixed Effects				
V _{pop} , liter	0.86	3.02	0.86	3.85
CL _{pop} , liter/h	0.09	2.11	0.09	2.10
beta1	2.35	1.20	2.40	3.03
beta2	0.18	3.41	0.22	2.86
F _{VAS}	0.86	0.34	0.86	0.30
Standard Deviation of the Random Effects				
omega_V	0.11	24.20	0.15	21.40
omega_CL	0.24	6.85	0.23	6.79
Error Model Parameters				
b	0.21	4.82	0.21	5.04

668 ^aV_{pop}, population typical value of volume of distribution; CL_{pop}, population typical value of
669 VAN clearance; F_{VAS}, scaling factor of VAS co-medication; omega_V, standard deviation
670 of random effects for volume of distribution; omega_CL, standard deviation of random
671 effects for VAN clearance; b, residual error parameter.

672 ^bRSE, relative standard error.

673 ^cA new data set combines original data set and the data set of external validation.

674 **TABLE 2** Baseline demographic characteristics and PK parameters in AKI analysis and efficacy analysis.

Variable ^a	AKI analysis ^b			Efficacy analysis		
	Normal patients (N=175)	AKI patients (N=7)	P	Effective patients (N=35)	Ineffective patients (N=7)	P
	median (range/proportion)	median (range/proportion)		median (range/proportion)	median (range/proportion)	
Maturation						
Gender	98/77 (male/female)	4/3 (male/female)	1.00	18/17 (male/female)	5/2 (male/female)	0.43
GA, wk	30.43 (22.29~41.29)	33.86 (24.71~40.00)	0.20	31.00 (24.43~40.00)	29.71 (26.29~33.29)	0.32
PNA, wk	2.24 (0.28~12.62)	0.85 (0.57~3.71)	<0.05	2.57 (0.93~5.00)	2.57 (0.85~4.43)	1.00
PMA, wk	33.33 (22.60~46.25)	34.78 (28.29~40.71)	0.48	33.81 (26.50~41.04)	32.28 (27.00~35.28)	0.32
bWT, kg	1.35 (0.55~4.40)	1.74 (0.77~3.05)	0.43	1.37 (0.70~3.03)	0.95 (0.77~1.18)	< 0.01
cWT, kg	1.58 (0.57~5.63)	1.80 (1.20~3.02)	0.57	1.58 (0.78~3.05)	1.25 (0.76~1.56)	< 0.01
Renal Function						
SCR, $\mu\text{mol/liter}$	26.70 (3.90~77.50)	85.90 (22.10~107.10)	<0.01	24.60 (9.60~55.21)	22.80 (10.70~44.40)	0.79
CLCR, (ml/min)/1.73m ²	35.33 (9.69~142.18)	19.73 (9.09~39.51)	<0.01	37.40 (17.55~81.95)	36.71 (22.37~51.40)	0.60
PK Parameters						
Daily dose, mg/kg	30.00 (13.33~63.22)	28.80 (19.35~46.69)	0.33	29.11 (15.48~44.26)	28.32 (18.42~58.97)	0.38
CL, liter/(h·kg)	0.06 (0.02~0.16)	0.03 (0.03~0.05)	<0.01	0.06 (0.04 ~ 0.16)	0.06 (0.05 ~ 0.12)	0.97
C _{min} , mg/liter	12.38 (3.11~33.01)	23.10 (12.51~51.36)	<0.01	13.48 (3.39~18.96)	11.38 (7.50~12.76)	< 0.05
AUC ₂₄ , (mg·h)/liter	468.70 (203.30~1118.40)	772.00 (476.90~1385.80)	<0.01	471.60 (272.10~627.80)	440.90 (325.60~485.10)	< 0.1
MIC, mg/liter	/	/	/	2.0 (0.5~2.0)	2.0 (2.0~2.0)	0.12

AUC ₂₄ /MIC	/	/	/	256.40 (136.00~1030.30)	215.60 (162.80~242.50)	< 0.01
Comorbidities						
PDA	74 (42.3%)	7 (100.0%)	<0.01	10 (28.6%)	3 (42.9%)	0.66
Pneumonia	74 (42.3%)	4 (57.1%)	0.46	8 (22.9%)	3 (42.9%)	0.35
BDP	41 (23.4%)	2 (28.6%)	0.67	5 (14.3%)	2 (28.6%)	0.27
Meningitis	36 (20.6%)	1 (14.3%)	1.00	4 (11.4%)	0 (0.00%)	1.00
NEC	31 (17.7%)	2 (28.6%)	0.61	5 (14.3%)	0 (0.00%)	0.57
PPHN	14 (8.00%)	2 (28.6%)	0.12	2 (5.71%)	0 (0.00%)	1.00
Co-medication						
Meropenem	82 (46.9%)	7 (100.0%)	<0.01	11 (31.4%)	2 (28.6%)	1.00
VAS	30 (17.1%)	6 (85.7%)	<0.01	2 (5.71%)	1 (14.3%)	0.43
Furosemide	26 (14.9%)	4 (57.1%)	<0.05	1 (2.86%)	1 (14.3%)	0.31
Ibuprofen	8 (4.57%)	0 (0.00%)	1.00	1 (2.86%)	0 (0.00%)	1.00
Outcome						
Mortality	13 (7.43%)	2 (28.6%)	0.10	0 (0.00%)	3 (42.9%)	< 0.01

675

676 ^aGA, gestational age; PNA, postnatal age; PMA, postmenstrual age; bWT, birth weight; cWT, current body weight; SCR, serum
677 creatinine; CLCR, creatinine clearance; CL, VAN clearance; Cmin, trough concentration; PDA, patent ductus arteriosus; BDP,
678 bronchopulmonary dysplasia; NEC, neonatal necrotic enterocolitis; PPHN, persistent pulmonary hypertension of newborn; VAS,
679 vasoactive drugs, which are referred to milrinone, dopamine, epinephrine, and norepinephrine in our institution.

680 ^bAKI, acute kidney injury.

681 **TABLE 3** Results of ULR and ROC analysis

Variable^a	OR (P)^b	AUC_{ROC} (95% CI)^c	Cut-off	SP^d	SE^e
AKI analysis					
AUC ₂₄ , (mg·h)/liter	1.01 (< 0.01)	0.89 (0.77~1.00)	623	0.85	0.86
Efficacy analysis					
AUC ₂₄ /MIC	1.02 (< 0.1)	0.81 (0.67~0.95)	242	0.86	0.66

682

683 ^aAKI, acute kidney injury.

684 ^bOR, Odds ratio and corresponding P value for univariate logistic regression.

685 ^cAUC_{ROC}, area under curve for ROC curve.

686 ^dSP, specificity of ROC analysis.

687 ^eSE, sensitivity of ROC analysis.

688

689

690

691

692

693

694

695

696 **TABLE 4** Results of MRL

Variable ^a	OR ^a (95%CI)	P
AKI analysis		
AUC ₂₄ ≥ 623 (mg·h)/liter	31.15 (3.21~302.00)	<0.01
Concomitant use of VAS	28.67 (2.95~278.52)	<0.01
Efficacy analysis		
AUC ₂₄ /MIC < 242	0.09 (0.01~0.97)	<0.05
cWT < 1.3kg	0.11 (0.01~0.80)	<0.05

697

698 ^aAKI, acute kidney injury.

699 ^bOR, adjusted odds ratio.

700

701

702

703

704

705

706

707

708

709

710

711 **TABLE 5 Dose recommendations in current references**

Reference	Age (wk) / SCR ($\mu\text{mol/liter}$) ^a	Dose recommendations ^b
Neonatal Formulary	PMA <29	20mg/kg,q24h
	PMA 30~33	20mg/kg,q18h
	PMA 34~37	20mg/kg,q12h
	PMA 38~44	15mg/kg,q8h
	PMA > 45	10mg/kg,q6h
Red Book	GA \leq 28	LD: 20mg/kg
	SCR <44.2	MD: 15mg/kg,q12h
	SCR 44.2~61.7	MD: 20mg/kg,q24h
	SCR 70.6~88.2	MD: 15mg/kg,q24h
	SCR 97.0~123.5	MD: 10mg/kg,q24h
	SCR >123.5	MD: 15mg/kg,q48h
	GA > 28	LD: 20mg/kg
	SCR <61.7	MD: 15mg/kg,q12h
	SCR 61.7~79.4	MD: 20mg/kg,q24h
	SCR 88.2~105.8	MD: 15mg/kg,q24h
	SCR 114.7~141.2	MD: 10mg/kg,q24h
SCR >141.2	MD: 15mg/kg,q48h	

712

713 ^aSCR, serum creatinine; PMA, postmenstrual age; GA, gestational age.

714 ^bLD, loading dose; MD, maintenance dose.

715

716

717

718

719

720

721 **TABLE 6 Results of dosing regimen simulation**

cWT^a	PMA^b	SCR^c	Patients without VAS^d	Patients with VAS
(kg)	(wk)	(μmol/liter)		
0.7~0.99	25~27	10	15~17.5mg/kg, q18h	17.5~20mg/kg, q24h
		25	12.5~15mg/kg, q18h	15~17.5mg/kg, q24h
		45	12.5~15mg/kg, q18h	12.5~15mg/kg, q24h
		60	10~12.5mg/kg, q18h	12.5~15mg/kg, q24h
		90	10~12.5mg/kg, q18h	12.5~15mg/kg, q24h
1.0~1.69	28~31	10	12.5~15mg/kg, q12h	15~17.5mg/kg, q18h
		25	10~12.5mg/kg, q12h	12.5~15mg/kg, q18h
		45	15~17.5mg/kg, q18h	12.5~15mg/kg, q18h
		60	12.5~15mg/kg, q18h	10~12.5mg/kg, q18h
		90	12.5~15mg/kg, q18h	10~12.5mg/kg, q18h
1.7~2.69	32~36	10	15~17.5mg/kg, q12h	12.5~15mg/kg, q12h
		25	12.5~15mg/kg, q12h	10~12.5mg/kg, q12h
		45	10~12.5mg/kg, q12h	15~17.5mg/kg, q18h
		60	10~12.5mg/kg, q12h	12.5~15mg/kg, q18h
		90	10~12.5mg/kg, q12h	12.5~15mg/kg, q18h
2.7~3.69	37~41	10	12.5~15mg/kg, q8h	15~17.5mg/kg, q12h
		25	10~12.5mg/kg, q8h	12.5~15mg/kg, q12h
		45	15~17.5mg/kg, q12h	12.5~15mg/kg, q12h
		60	12.5~15mg/kg, q12h	10~12.5mg/kg, q12h
		90	12.5~15mg/kg, q12h	10~12.5mg/kg, q12h
3.7~4.6	42~46	10	15~17.5mg/kg, q8h	12.5~15mg/kg, q8h

25	12.5~15mg/kg, q8h	10~12.5mg/kg, q8h
45	10~12.5mg/kg, q8h	15~17.5mg/kg, q12h
60	10~12.5mg/kg, q8h	12.5~15mg/kg, q12h
90	10~12.5mg/kg, q8h	12.5~15mg/kg, q12h

722

723 ^acWT, current body weight.

724 ^bPMA, postmenstrual age.

725 ^cSCR, serum creatinine.

726 ^dVAS, vasoactive drugs.